在二次数据源中预测赎回处方的治疗指示的新数据驱动方法:丹麦登记处所发现的65岁或以上的抗发作药物使用者的案例研究
Israa Mahmoud1, Vera Battini1,2, Carla Carnovale2
1Department of Drug Design and Pharmacology, University of Copenhagen, Kobenhavn, Denmark.
BMJ open
|June 6, 2024
概括
一种新的数据驱动方法使用丹麦注册数据准确地预测了老年患者抗药物的治疗指示. 该算法对在这个人群中识别药物使用有希望.
科学领域:
- 药学流行病学 药学流行病学
- 医疗信息学 医疗信息学
- 老年医学 老年医学
背景情况:
- 在现实数据中准确识别药物的治疗指示对于药物流行病学研究至关重要.
- 患有的老年人 (≥65岁) 经常使用抗药物 (AED),需要可靠的方法来从二级数据源中确定他们的治疗指示.
研究的目的:
- 开发和评估一种新的数据驱动算法,用于预测赎回的抗药物处方的治疗指示.
- 通过使用丹麦注册数据,评估算法在65岁及以上患者群体中的性能.
主要方法:
- 从2005年到2017年,丹麦进行了一项基于登记的队列研究.
- 这项研究包括65岁及以上的抗药物新用户,并确认了的诊断.
- 灵敏度是预测算法的主要性能指标.
主要成果:
- 研究群体包括8609例抗药物新使用者.
- 开发的算法在正确预测AEDs的治疗指示方面获得了65.3% (95% CI 64.4至66.2) 的灵敏度.
- 这表明算法正确识别了大约六分之十个人的治疗适应症.
结论:
- 数据驱动的算法在预测患者的老年人中赎回的抗药物处方的治疗指示方面显示出有希望的表现.
- 这种方法可以帮助更准确的药理流行病学研究,利用这个特定的患者群体的二次数据源.
更多相关视频
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.1K
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
15.7K
相关概念视频
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
